The realm of drug discovery is constantly seeking innovative technologies that can expedite the process of uncovering new medicines. On the 17th of July, 2024, HitGen Inc. and Xtalks will be hosting a live webinar entitled “Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery,” where esteemed experts will deliberate the latest advancements in DNA-Encoded Library (DEL) technology and its impact on drug discovery.
DEL technology has been making significant strides in recent years, offering novel methods to identify hit compounds with the potential to evolve into the next generation of drugs. During the webinar, Dr. Alex Shaginian, Dr. David Israel, and Dr. Rusty Montgomery will provide insights into the challenges of drug discovery and the various selection strategies for DEL technology. They will also present a case study from BioAge Labs, illustrating the discovery of novel inhibitors using DEL technology.
The webinar will illuminate the various target types that can be explored using DEL technology, from enzymes to receptors, and underscore the unique advantages of applying DELs to these targets. Additionally, the speakers will discuss the different DEL platforms that have been developed and how they can be utilized to achieve success in the drug discovery process.
A notable feature of the webinar will be a case study presented by BioAge Labs, where they will share their experience utilizing DEL technology for the discovery of potent indazole NLRP3 inhibitors. The selection strategy employed in the study allowed researchers to directly identify small molecule structures, as well as evaluate their biophysical and biochemical activities, physicochemical properties, and other factors.
For those with an interest in the future of small-molecule drug discovery, this webinar presents an opportunity to gain invaluable insights into the potential of DEL technology.
HitGen Inc., headquartered in Chengdu, China, is at the forefront of drug discovery research, with subsidiaries in Cambridge, UK and Houston, USA. The company has established leading technology platforms for the discovery and optimization of small molecules and nucleic acid drugs, including DNA-encoded library technology (DEL), fragment-based drug discovery, and structure-based drug design technologies.
The work carried out by HitGen and other companies in the field of drug discovery is a testament to the ongoing efforts to uncover new and effective treatments for a wide range of diseases. Through collaborative partnerships with biopharmaceutical research organizations worldwide, HitGen is driving multiple programs from early discovery to clinical trial stages, all in pursuit of creating a healthier future for all.
For those seeking more information about the webinar, including registration details, please visit the official event page.
To stay abreast of HitGen’s latest news and developments, please visit www.hitgen.com.